8 Articles found

FluGen, Inc. articles

FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years

MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old. This study is the first of its kind

Sep. 7, 2022

Katie Radspinner

FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population –
Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 –

MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the dosing of i

Jun. 22, 2022

Katie Radspinner

FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain –

MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, li

Aug. 2, 2021

Katie Radspinner

FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine

Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu –

Safety and immunogenicity study expected to begin in Q2 2022 –

MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory disea

Jun. 1, 2021

Katie Radspinner

FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85

Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu –

Topline data expected in 1H 2022 –

MADISON, Wis., May 25, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the first study in older adults of M2SR, the company’s investigational supr

May. 25, 2021

Katie Radspinner